Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Provides Update on Ownership Interest in Haleon

Business Wire June 1, 2022

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability

Business Wire May 31, 2022

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Business Wire May 26, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire May 25, 2022

Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries

Business Wire May 25, 2022

Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

Business Wire May 24, 2022

Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Business Wire May 17, 2022

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

PR Newswire May 12, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd. Buyout

Newsfile May 11, 2022

BIOHAVEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN

PR Newswire May 10, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

PR Newswire May 10, 2022

Pfizer to Acquire Biohaven Pharmaceuticals

Business Wire May 10, 2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

GlobeNewswire May 6, 2022

Pfizer Reports First-Quarter 2022 Results

Business Wire May 3, 2022

MOBI Makes Their Post-Pandemic NYC Debut

PR Newswire May 2, 2022

Pfizer Declares Second-Quarter 2022 Dividend

Business Wire April 28, 2022

Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

Business Wire April 27, 2022

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

Business Wire April 26, 2022

Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28

Business Wire April 19, 2022

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Business Wire April 14, 2022